{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:52:45Z","timestamp":1793137965506,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T00:00:00Z","timestamp":1479772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.clinthera.2016.11.017","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T10:01:15Z","timestamp":1481364075000},"page":"118-129.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study"],"prefix":"10.1016","volume":"39","author":[{"given":"Brian","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Jesaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Slasor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Schweighardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.11.017_bib1","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/humu.22635","article-title":"Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locus-specific database","volume":"35","author":"Morrone","year":"2014","journal-title":"Hum Mutat"},{"key":"10.1016\/j.clinthera.2016.11.017_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004390050641","article-title":"Incidence of the mucopolysaccharidoses in Northern Ireland","volume":"101","author":"Nelson","year":"1997","journal-title":"Hum Genet"},{"key":"10.1016\/j.clinthera.2016.11.017_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajmg.a.20314","article-title":"Incidence of the mucopolysaccharidoses in Western Australia","volume":"123A","author":"Nelson","year":"2003","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2016.11.017_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2013.04.009","article-title":"Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder","volume":"109","author":"Yasuda","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2016.11.017_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2016.11.017_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","article-title":"Review of clinical presentation and diagnosis of Mucopolysaccharidosis IVA","volume":"110","author":"Hendriksz","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2016.11.017_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10545-013-9586-2","article-title":"Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management","volume":"36","author":"Solanki","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2016.11.017_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymgme.2014.10.015","article-title":"Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome","volume":"114","author":"Harmatz","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2016.11.017_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","article-title":"Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey","volume":"9","author":"Hendriksz","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2016.11.017_bib10","first-page":"59","article-title":"Mortality in patients with Morquio syndrome A","volume":"15","author":"Lavery","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.clinthera.2016.11.017_bib11","series-title":"Vimizim (elosulfase alfa) [prescribing information]","year":"2014"},{"key":"10.1016\/j.clinthera.2016.11.017_bib12","doi-asserted-by":"crossref","first-page":"e12194","DOI":"10.1371\/journal.pone.0012194","article-title":"Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice","volume":"5","author":"Dvorak-Ewell","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2016.11.017_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clinthera.2016.11.017_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.clinthera.2016.11.017_bib15","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.clinthera.2015.06.004","article-title":"Enzyme replacement therapies and immunogenicity in lysosomal storage diseases: is there a pattern?","volume":"37","author":"Harmatz","year":"2015","journal-title":"Clin Therapeutics"},{"key":"10.1016\/j.clinthera.2016.11.017_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2016.11.017_bib17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.clinthera.2014.11.005","article-title":"Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial","volume":"37","author":"Schweighardt","year":"2015","journal-title":"Clin Therapeutics"},{"key":"10.1016\/j.clinthera.2016.11.017_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2016.05.018","article-title":"Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome","volume":"119","author":"Hendriskz","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2016.11.017_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2016.11.017_bib20","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2016.11.017_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2013Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2016.11.017_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","article-title":"Pre-existing antibody: biotherapeutic modality-based review","volume":"18","author":"Gorovits","year":"2016","journal-title":"AAPS Journal"},{"key":"10.1016\/j.clinthera.2016.11.017_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in disease treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.clinthera.2016.11.017_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.beem.2015.01.006","article-title":"The role of antibodies in enzyme treatments and therapeutic strategies","volume":"29","author":"Bigger","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2016.11.017_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","article-title":"Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: a comprehensive meta-analysis of pooled data from multiple studies","volume":"117","author":"Xue","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2016.11.017_bib26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40262-014-0173-y","article-title":"Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome","volume":"53","author":"Qi","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2016.11.017_bib27","series-title":"Aldurazyme (laronidase) [prescribing information]","year":"2013"},{"key":"10.1016\/j.clinthera.2016.11.017_bib28","series-title":"Naglazyme (galsulfase) [prescribing information]","year":"2013"},{"key":"10.1016\/j.clinthera.2016.11.017_bib29","unstructured":"BioMarin Pharmaceutical. Vimizim (elosulfase alfa) for the treatment of mucopolysaccharidosis type IV A (Morquio A syndrome). Briefing document for the Endocrinologic and Metabolic Drugs Advisory Committee.http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM375127.pdf. Accessed 2016."},{"key":"10.1016\/j.clinthera.2016.11.017_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"11","key":"10.1016\/j.clinthera.2016.11.017_bib31","first-page":"CD009354","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I","author":"Jameson","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816308554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816308554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T20:52:55Z","timestamp":1658004775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816308554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0149291816308554"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}